Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Peto, Thomas J ^a,b,c   Mendy, Maimuma E ^a,d   Lowe, Yamundow ^e   Webb, Emily L ^b   Whittle, Hilton C ^a,b   Hall, Andrew J ^b,d  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e MINISTRY OF HEALTH AND SOCIAL WELFARE   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMBIA; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERVENTION STUDY; LIVER FUNCTION TEST; MALE; PRESCHOOL CHILD; PREVALENCE; PREVENTIVE HEALTH SERVICE; RURAL AREA; SCHOOL CHILD; SEROLOGY; SEX DIFFERENCE; VACCINATION; BIRTH; BLOOD; CASE CONTROL STUDY; COMMUNICABLE DISEASE; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; HEPATITIS B, CHRONIC; HEPATITIS, CHRONIC; IMMUNOLOGY; INFANT; TREATMENT OUTCOME; YOUNG ADULT;

CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMMUNICABLE DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GAMBIA; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INTERVENTION STUDIES; MALE; PARTURITION; PREVALENCE; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84892164291     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-7     Document Type: Article

References (30)

1. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepatitis 2007, 14:6-10.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009, 373(9663):582-592. 10.1016/S0140-6736(09)60207-5, 19217993.
3. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000, 462(2-3):381-393.
4. Sylla BS, Wild CP. A million Africans a year dying from cancer by 2030: What can cancer research and control offer to the continent?. Int J Cancer 2012, 130(2):245-250. 10.1002/ijc.26333, 3244688, 21796634.
5. International Agency for Research on Cancer Hepatitis B Virus. A review of human carcinogens. Part B: Biological agents. IARC monographs on the evaluation of carcinogenic risks to humans Volume 100B 2012, 93-133. Lyon, France: IARC, International Agency for Research on Cancer.
6. World Health Organisation Hepatitis B vaccines: WHO position paper. Weekly Epidemiol Record 2009, 84(40):405-419. World Health Organisation.
7. Chotard J, Inskip HM, Hall AJ, et al. The Gambia Hepatitis Intervention Study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992, 166(4):764-768. 10.1093/infdis/166.4.764, 1388196.
8. Fortuin M, Chotard J, Jack AD, et al. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 1993, 341(8853):1129-1131. 10.1016/0140-6736(93)93137-P, 8097813.
9. Hall AJ, Inskip HM, Loik F, et al. for the gambia hepatitis study group. The gambia hepatitis intervention study. Cancer Res 1987, 47(21):5782-5787.
10. Hall AJ, Inskip HM, Loik F, et al. for the Gambia Hepatitis Study Group. Hepatitis B vaccine in the expanded programme of immunisation: The Gambian experience. Lancet 1989, 333(8646):1057-1060.
11. Viviani S, Carrieri P, Bah E, et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(11):3216-3223. 10.1158/1055-9965.EPI-08-0303, 18990765.
12. van der Sande MA, Mendy M, Waight P, et al. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 2007, 25(8):1509-1512. 10.1016/j.vaccine.2006.10.023, 17095130.
13. van der Sande MA, Waight P, Mendy M, et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006, 193(11):1528-1535. 10.1086/503433, 16652281.
14. van der Sande MA, Waight PA, Mendy M, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One 2007, 2(8):e753. 10.1371/journal.pone.0000753, 1940311, 17710152.
15. Viviani S, Jack A, Hall AJ, et al. Hepatitis B vaccination in infancy in the gambia: protection against carriage at 9 years of age. Vaccine 1999, 17(23-24):2946-2950.
16. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002, 325(7364):569-573. 10.1136/bmj.325.7364.569, 124550, 12228132.
17. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in the gambia. Lancet 1991, 337(8744):747-750. 10.1016/0140-6736(91)91367-4, 1672389.
18. Hall AJ. Hepatitis B, vaccination: protection for how long and against what?. BMJ 1993, 307(6899):276-277. 10.1136/bmj.307.6899.276, 1678572, 8374369.
19. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179(2):489-492. 10.1086/314578, 9878036.
20. Wenzel JJ, Jilg W. Loss of antibodies, but not of protection. Lancet Infect Dis 2010, 10(11):738-739. 10.1016/S1473-3099(10)70217-6, 21029981.
21. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993, 253(1337):197-201. 10.1098/rspb.1993.0102, 8397416.
22. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26(49):6266-6273. 10.1016/j.vaccine.2008.09.056, 18848855.
23. Romano L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011, 43(Suppl 1):S2-S7.
24. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28(3):623-631. 10.1016/j.vaccine.2009.10.068, 19887132.
25. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Cancer in indigenous Africans. Part I: Burden, distribution, and trends. Lancet Oncol 2008, 9(7):683-692. 10.1016/S1470-2045(08)70175-X, 18598933.
26. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002, 2(5):293-302. 10.1016/S1473-3099(02)00264-5, 12062995.
27. Mboto CI, Davies-Russell A, Fielder M, Jewell AP. Hepatitis C antibodies in asymptomatic first-time blood donors in The Gambia: prevalence and risk factors. Br J Biomed Sci 2005, 62(2):89-91.
28. Kirk GD, Lesi OA, Mendy M, et al. The gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004, 39(1):211-219. 10.1002/hep.20027, 14752840.
29. Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis 2011, 15(2):e78-e121. 10.1016/j.ijid.2010.09.005, 21130675.
30. Whittle HC, Inskip H, Bradley AK, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990, 161(6):1112-1115. 10.1093/infdis/161.6.1112, 2345294.